Dupixent (dupilumab) and Adbry (tralokinumab) are FDA-approved biologic therapies for those with severe eczema that do not ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Sanofi’s Dupixent (dupilumab ... the first topical treatment specifically approved for chronic hand eczema (CHE).

The quicker a person recognizes and responds to symptoms, the better the treatment outcome. Doctors can often treat the causes of infected eczema with prescription medications. Depending on what ...

Atopic dermatitis, also known as atopic eczema ... to current standard treatments." Sanofi to increase competition in atopic dermatitis market after Dupixent’s success - (https ...

A dermatologist can diagnose papular eczema and help develop a treatment plan. The type of medication they recommend can depend on whether symptoms are mild or severe, as well as whether treatment ...

Biologic treatments are a new option for people ... might also prescribe these medicines off-label for other types of eczema. Dupixent and Adbry are “monoclonal antibodies.” ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...